Biopharma Product Manager & Business Analyst
Send a job offer directly to this candidate
I am an accomplished pharmaceutical IT product manager and business analyst, experienced in biopharma business development, clinical development and operations, regulatory, pharmacovigilance, medical affairs and marketing.
President & COO
Life Science Nation (LSN), Boston Q2 2024 - Present
LSN provides the RESI partnering conferences, investor, pipeline and deals databases, entrepreneurial education, and investor meeting arrangement in the world of biotech investment & BD.
I lead the operations of the company, including marketing, investor, deals & pipeline database development & editorial, IT, customer service, event planning, and India outsourcing. Databases are commercialized as Biotechgate and the LSN Investor Database, and power the RESI partnering system, investor meeting arrangement services and AI-powered pitch deck preparation services.
Since I started as COO, LSN revenue grew 25% in the first year and is on track to grow another 25% this year. Prior, revenue was flat for 3 years. I manage a team of 15.
General Manager, Biotech Partnering & Data
Inpart (formerly Inova), Lyon, France Q3 2022 – Q1 2024
Inpart provides the business development CRM used by most large pharma BD departments, BIO’s partnering system (also used by other partnering conferences), and a tech transfer marketplace.
I led the biotech partnering & data unit, responsible for product management/ development, sales, marketing, finance, customer service, editorial, and India outsourcing. I commercialized BIO’s partnering system, integrated with Cortellis, to numerous other conference providers including LSX, Advanced Therapies Week, and Biocom. I also led the data integration and AI initiatives that took intelligence from the partnering system and integrated it into Inpart’s BD CRM to provide fast access to competitive intelligence in the pharma BD workflow.
I managed a team of 10.
BIO 2022 Management Consultant, Marketing
Biotechnology Innovation Organization (BIO), Washington, D.C. Q1 2022 – Q3 2022
With BIO’s former marketing team of 13 made redundant and 2 new hires experienced in neither biotech nor event marketing, BIO management worried BIO 2022, one of the first major ‘post-Covid’ in-person events, would underperform. I was asked to lead marketing for the event based on my previous history at BIO.
Executive Vice President & Co-founder
Prism Science (now part of Cellix Bio), New York, NY Q3 2019 – Q1 2022
Prism Science, now merged with Cellix Bio, provided intelligence to large pharma R&D, medical affairs and pharmacovigilance. Additionally, it provided advertising solutions to large pharma commercial.
I functioned as a COO, leading all functions except sales and finance.
Science gathered a tremendous amount of biomedical intelligence, indexed it to leading ontologies, curated it both manually and via machine learning, and commercialized it as SaaS offerings and services. Information was gathered annually from 50+ citation indexes, 10K+ biomedical conferences, 300+ grant databases, 40+ clinical trial registries and 15+ pre-print servers. Patents were licensed from IFI Claims.
Science was on the path to provide the largest database of biomedical research output in existence, surpassing Embase, WoS and others. Content was productized as a search engine, a pipeline database, a KOL identification and profiling solution, and a ML-powered literature monitoring solution. Content was also leveraged to do bespoke medical affairs projects on share of voice. Finally, content was productized as a differentiated physician newsletter, supported by drug advertising.
Vice President of Product Management
Pharmaspectra, now part of IQVIA, New York, NY Q3 2017 – Q3 2019
Pharmaspectra, formerly Medmeme and currently part of IQVIA, provided KOL identification & profiling, share of voice, clinical trials search, and medical meeting abstracts search solutions.
I led product management taking all legacy products and modernizing them. I also led the development of a drug labeling intelligence solution. The company was sold to private equity before its completion.
I also led consulting and product implementation/integration engagements with large pharma clients including engagements on which KOLs, journals and medical meetings to choose in order to disseminate core messages, what core messages to lead with based on analysis of RWE and existing research trends, and how to integrate with the CRMs used by MSLs to optimize medical comms.
Biotechnology Innovation Organization (BIO), Washington, D.C. Q3 2013 – Q2 2017
Led software product management, customer service, logistics and business development for the primary revenue generating division for the world’s largest biotech trade organization. This led to a 50% increase in revenue over 4.5 years, from $20M to $30M.
Sr. Product Manager
Thomson Reuters Life Sciences, now Clarivate, Philadelphia, PA Q3 2008 – Q3 2013
Created and launched Clarivate’s key and still current life science intelligence platforms and one product
Product Manager, Philadelphia, PA
Liquent, now part of Perceptive Q3 2005 – Q3 2008
Led product management for pharmaceutical regulatory software solutions related to regulatory information management, eCTD management, regulatory publishing, and regulatory document management. This product portfolio generated $40M of revenue.
MS, Information Science The Pennsylvania State University
BS, Electrical Engineering The Pennsylvania State University
